Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot help with low sex drive?
The O-Shot is not a primary libido treatment. It may indirectly improve sexual confidence or interest for some women if dryness, discomfort, reduced sensation, or fear of pain are reducing desire, but low sex drive can be hormonal, psychological, relational, medication-related, fatigue-related, or linked to pain and menopause.
Direct answer
The O-Shot is not a primary libido treatment. It may indirectly improve sexual confidence or interest for some women if dryness, discomfort, reduced sensation, or fear of pain are reducing desire, but low sex drive can be hormonal, psychological, relational, medication-related, fatigue-related, or linked to pain and menopause.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
Hormonal (Local/Systemic)
Hormonal (Local/Systemic):
Topical Oestrogen (creams, pessaries, rings).
Topical Oestrogen (creams, pessaries, rings).
Systemic HRT (tablets, patches, gels).
Systemic HRT (tablets, patches, gels).
Testosterone
Prescribed "off-label" for Hypoactive Sexual Desire Disorder (HSDD).
Important safety note
Clinical Red Flags (Immediate GP Review Required): Unexplained postmenopausal bleeding (PMB), new genital lumps or ulcers, and persistent pelvic pain.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
The disparity between device marketing and regulatory consensus remains a significant concern for clinical governance. NICE Regulatory Position: IPG615 (2018): Specifically refers to Microwave treatment; evidence for efficacy is "limited in quality and quantity."
Clinical context
NICE Regulatory Position:
Evidence
Symptoms
Alternatives
What it means
NICE Regulatory Position:
Why it happens
IPG615 (2018): Specifically refers to Microwave treatment; evidence for efficacy is "limited in quality and quantity."
Evidence limits
IPG696 (SUI) & IPG697 (GSM/Atrophy): Classify evidence for long-term safety as "inadequate," recommending use only under "Special Arrangements" for audit and research.
Treatment fit
Evidence Quality:
What this means in practice
Adherence to Care Quality Commission (CQC) and General Medical Council (GMC) standards is mandatory: CQC Scope: Registration is mandatory for "surgical procedures," defined to include instruments inserted into the body, liposuction, and all thread lifting.
Therapeutic efficacy and regulatory reflection periods follow specific clinical timelines: O-Shot (PRP): Initial tissue changes typically observed at 4–6 weeks; peak regenerative outcomes achieved at 3 months.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
NICE Regulatory Position:
It protects safety
Clinical Red Flags (Immediate GP Review Required): Unexplained postmenopausal bleeding (PMB), new genital lumps or ulcers, and persistent pelvic pain.
It reviews alternatives
CQC Scope: Registration is mandatory for "surgical procedures," defined to include instruments inserted into the body, liposuction, and all thread lifting.
It sets expectations
O-Shot (PRP): Initial tissue changes typically observed at 4–6 weeks; peak regenerative outcomes achieved at 3 months.
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
Adherence to Care Quality Commission (CQC) and General Medical Council (GMC) standards is mandatory: CQC Scope: Registration is mandatory for "surgical procedures," defined to include instruments inserted into the body, liposuction, and all thread lifting.
Consultation priorities
Primary Assessment: Initial GP consultation and referral.
Consent
Aftercare
Follow-up
Before treatment
Primary Assessment: Initial GP consultation and referral.
During care
Specialist Consultation: Direct meeting with the surgeon/clinician performing the procedure.
Aftercare
Medical Trial: Mandatory trial of conservative and medical therapies (Physio/Oestrogen) before interventional steps.
When to reassess
The Cooling-Off Period: A minimum 14-day reflection period following the procedural consultation.
Practical expectations
O-Shot (PRP): Initial tissue changes typically observed at 4–6 weeks; peak regenerative outcomes achieved at 3 months.
Professional Verification: Patients must verify that the practitioner is on the GMC Specialist Register, not merely holding general registration.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: Low sex drive is resolved by increasing genital sensitivity.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: The O-Shot is a libido injection.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: Arousal, desire, and orgasm are all the same thing.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
IPG615 (2018): Specifically refers to Microwave treatment; evidence for efficacy is "limited in quality and quantity."
Alternatives
CQC Scope: Registration is mandatory for "surgical procedures," defined to include instruments inserted into the body, liposuction, and all thread lifting.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Clinical Red Flags (Immediate GP Review Required): Unexplained postmenopausal bleeding (PMB), new genital lumps or ulcers, and persistent pelvic pain.
Are alternatives clear?
CQC Scope: Registration is mandatory for "surgical procedures," defined to include instruments inserted into the body, liposuction, and all thread lifting.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Clinical Red Flags (Immediate GP Review Required): Unexplained postmenopausal bleeding (PMB), new genital lumps or ulcers, and persistent pelvic pain.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
Clinical Red Flags (Immediate GP Review Required): Unexplained postmenopausal bleeding (PMB), new genital lumps or ulcers, and persistent pelvic pain.
Bleeding or discharge
Breast Cancer/Tamoxifen Interactions:
Infection signs
Paroxetine/Fluoxetine: Must be avoided as they inhibit the cytochrome P450 enzyme (CYP2D6) required to metabolise Tamoxifen.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- WHC can win by separating desire from sensation, which most competitor pages blend together.
Clinical reality
- NICE Regulatory Position:
- IPG615 (2018): Specifically refers to Microwave treatment; evidence for efficacy is "limited in quality and quantity."
- IPG696 (SUI) & IPG697 (GSM/Atrophy): Classify evidence for long-term safety as "inadequate," recommending use only under "Special Arrangements" for audit and research.
- Evidence Quality:
- PRP/O-Shot is currently "investigational" due to high heterogeneity in preparation protocols.
- Pyrgidis et al. (2023) observed significant increases in orgasm and lubrication (p < 0.05), yet Waghe et al. (2024) found no statistically significant improvement compared to placebo.
Timeline and expectations
- O-Shot (PRP): Initial tissue changes typically observed at 4–6 weeks; peak regenerative outcomes achieved at 3 months.
- Testosterone Therapy: Restoration of libido and arousal intensity typically requires 3–6 months of consistent application to reach therapeutic levels.
- Clinical Decision Making: A mandatory 14-day "cooling-off" period is required between initial surgical consultation and the performance of interventional procedures.
- Vasomotor Symptom Profile: Vasomotor symptoms (VMS) such as hot flushes persist for an average of 7 years.
Practical logistics
- CQC Scope: Registration is mandatory for "surgical procedures," defined to include instruments inserted into the body, liposuction, and all thread lifting.
- Professional Verification: Patients must verify that the practitioner is on the GMC Specialist Register, not merely holding general registration.
- Governance: Energy device use requires "Special Arrangements," including systematic data auditing and informed consent that explicitly discloses the limited evidence for long-term efficacy.
- Cost Transparency: Full written cost estimates must be provided in advance by law.
Research sources
- VIVEVE I Trial: Krychman M, et al. (2017). Randomized, sham-controlled study regarding radiofrequency for vaginal laxity.
- PRP Systematic Review: Pyrgidis et al. (2023). Analysis of FSFI improvements in lubrication and orgasm domains.
- BMS Consensus: (2023/2024 Update). Non-hormonal-based treatments for menopausal symptoms (Venlafaxine/Clonidine/Gabapentin dosages).
- NICE IPG615: (2018). Guidance on microwave treatment for severe menopausal symptoms; used in context with IPG696 (SUI) and IPG697 (GSM).
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE guidance on vaginal laser for urogenital atrophy
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Full Research Bibliography (10 Sources)
Educational only. Information is for educational use only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical suitability must be determined by a qualified professional; results may vary and these treatments are not considered a 'cure'. In medical emergencies, contact NHS 111 or 999 immediately. Results vary. Not a cure.
